Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PIRAD remifentanil-dexmedetomidine interaction study
2017-000945-37Phase 4Completed
- Sponsor
- University Medical Center Groningen
- Start
- Apr 2017
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of dexmedetomidine and remifentanil, sponsored by University Medical Center Groningen. Primary endpoint: PK/PD relationship of dexmedetomidine and remifentanil with cerebral, hemodynamic, and respiratory effects. Started Apr 2017; status: completed.
02
Drugs
dexmedetomidineremifentanil
Beyond the preview
Go deeper on 2017-000945-37.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-000945-37.